YELLOW FEVER: EPIDEMIOLOGY, CLINIC, DIAGNOSTICS AND PREVENTION
DOI:
https://doi.org/10.11603/1681-2727.2018.4.9775Keywords:
yellow fever, mosquitoes of the genus Aedes, biological safety, bleeding, pathogenetic therapy, preventionAbstract
The aim of the work is to summarize the data on etiology, epidemiological features, clinical manifestations and laboratory diagnostics of yellow fever (YF), to submit the main recommendations of the WHO and the CDC in relation to its prevention and treatment.
The most recent data about YF, the peculiarities of its distribution are given. The YF virus (YFV) belongs to the Flavivirus family. The main reservoir of the pathogen in the nature is monkeys, additional – perhaps hedgehogs, marsupials, rodents, in which the infection duration can be latent. YFV gets into the person by biting an infected mosquito. The disease is registered in tropical areas of Africa and Central and South America. The natural epidemiology of YF on both continents – is the circulation of the virus between forest mosquitoes and wild primates. The transmission to a human occurs in forest (jungle, rural), intermediate and urban focuses. The urban transmission cycle is the most dangerous epidemiologically, which is implemented among non-immune people, as a result of the infected persons’ movement, or by accidently transporting of the infected mosquitoes. The severe clinical course and complications testify a special danger of this disease for humanity. The incubation period is usually 3–6 days, it can rarely reach 10 days. Typically, there are three periods of illness: an initial febrile, a period of remission with decrease of body temperature and a period of venous stasis. Mortality is 5–10 %, during the epidemic – up to 60 % and above. For YF light, abortive forms of the disease without jaundice and hemorrhagic syndrome are also possible. For the diagnosis verification within 5 days from the onset of symptoms, a polymerase chain reaction with reverse transcription and serological diagnosis (ELISA) are used. An effective etiotropic method of treatment has not yet been developed, only pathogenetic remedies are used. Currently, the only way to fight this infection, according to WHO and CDC recommendations, is immunization. Vaccinations should be done at least 10 days before travel in the endemic area. Employees of specialized laboratories in the risk group of infection and must be vaccinated. Since July 11, 2016, the WHO has decided to exclude re-vaccination, because a single dose provides lifelong immunity.
References
Barrett, A.D., & Monath, T.P. (2003). Epidemiology and ecology of yellow fever virus. Advances in Virus Research, 61, 291-315.
Gardner, Ch.L., & Ryman, K.D. (2010). Yellow Fever: A reemerging threat. Сlinics in Laboratory Medicine, 30 (1), 237-260, doi: [10.1016/j.cll.2010.01.001].
Tomlinson, W., & Hodgson, R.S. (2005). Centennial year of yellow fever eradication in New Orleans and the United States, 1905-2005. La State Medical Society, 157 (2), 216-217.
Staples, J.E., & Monath, T.P. (2008) Yellow fever: 100 years of discovery. JAMA, 300 (8), 960-962.
Gould, E.A., & Solomon, T. (2008). Pathogenic flaviviruses. Lancet, 9611 (371), 500-509.
Chambers, T.J., McCourt, D.W., & Rice, C.M. (1990). Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology, 177 (1), 159-174.
Waigmann, H., Deres, K., Hewlett, G., & Welker, L. (2001) Viral infections and treatment. Marsel Dekker, inc. New York: Basel, 590.
Fernandez-Garcia,M.D., Mazzon M., Jacobs M., & Amara, A. (2009). Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe, 5 (4), 318-328.
Monath, T.P. Pathogenesis and pathophysiology of yellow fever. Advances in Virus Research, 60, 343-395. doi: 10.1016/S0065-3527(03)60009-6.
Monath, T.P. (1999). Facing up to re-emergence of urban yellow fever. Lancet, 9164 (353), 1541.
Bres, P.L. (1986). A century of progress in combating yellow fever. Bull World Health Organ, 64 (6), 775-786.
Monath, T.P. (2006). Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bulletin de la Société de Pathologie Exotique, 99 (5), 341-347.
Monath, T.P. (2001). Yellow fever: an update. Lancet Infect Dis., 1 (1), 11-20.
Brunette, G.W., Kozarsky, P.E., Magill, A.J. (2009). CDC health information for international travel 2010. Elsevier, Online.
Briand, S. Beresniak, A., & Nguyen, T. (2009). Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLоS Neglected Tropical Diseases, 3, 483.
Bryant, J.E., Holmes, E.C., & Barrett, A.D., (2007). Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathogens, 5 (3), 75.
Monath, T.P. (1991). Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. The American Journal of Tropical Medicine and Hygiene, 45 (1), 1-43.
Barrett, A.D., Higgs, S. (2007). Yellow fever: a disease that has yet to be conquered. Annual Review of Entomology, 52, 209-229.
Mutebi, J.P., Wang, H., & Bryant, J.E. (2004) Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. Journal of Virology, 75, 6999-7008.
Monath, T.P., & Cetron, M.S. (2002). Prevention of yellow fever in persons traveling to the tropics. Clinical Infectious Diseases, 34 (10), 1369-1378.
Onyango, C.O., Ofula, V.O., Sang, R.C. (2004). Yellow fever outbreak, Imatong, southern Sudan. Emerging Infectious Diseases Journal, 10 (6), 1063-1068.
Monath, T.P. (2008). Treatment of yellow fever. Antiviral Research, 78 (1), 116-124.
Lvov, D.K., Alekseev K.P., Alimbarova, L.M., Alimper, T.I., Alhovskiy, S.V., Andronova, L.V… & Yuzakov, A.G. (2013). Rukovodstvo po virusologii. Virusy i virusnyie infektsii cheloveka i zhivotnykh [Virology guide. Viruses and viral infections of humans and animals]. Moscow: MIA [in Russian].
WHO. (2016). Yellow fever Outbreak. The Uganda Experience. ARCI meeting. Dar es Salaam, Tanzania, May. https://reliefweb.int/disaster/ep-2016-000059-uga
Barnett, E.D. (2007). Yellow fever: epidemiology and prevention. Clin. Infect. Dis., 44, 850-856.
(2018). Zhovta lykhomanka: shcho potribno znaty ta yak uberehtysia? [Yellow fever: what you need to know and how to be protected?]. Retrieved from: https://phc.org.ua/news/show/zhovta-lihomanka-shcho-potribno-znati-ta-yak-uberegtisya?fbclid=IwAR1L3UFMGo_IW0NK4vhp4HvD5yRbETRJUr4_7vtxzMApGReSXMnXDo9IYOg [in Ukrainian]
Pan American Health Organization; World Health Organization. (2017). Laboratory diagnosis of yellow fever virus infection. http://www.paho.org/ (last accessed 15 March 2017).
CDC (2017). CDC health information for international travel (Yellow Book). Chapter 3: infectious diseases related to travel – yellow fever. https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/yellow-fever.
Drosten, C. (2002). Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. Journal of Clinical Microbiology, 40, 2323-2330.
Domingo, C., Patel, P., & Yillah, J. (2012). Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. Journal of Clinical Microbiology, 50, 4054-4060.
World Health Organization. (2017). Yellow fever: case definitions for public health surveillance. https://www.who.int/ith/updates/20160727/en/.
Andreichyn, M.A., Zavidniuk N.H., & Nychyk, N.A. (2016). Problemy khvoroby Zika u sviti [Problems of Zika’s disease in the world]. Infektsiini khvoroby – Infectious Diseases, 1 (83), 56-62 [in Ukrainian]
Bestpractice (2016). Yellow fever. https://bestpractice.bmj.com/topics/uk-ua/906/differentials.
Andreichyn, M.A., Vasylieva, N.A., Ivakhiv, O.L., Ishchuk, I.S., Kachor, V.O., Kopcha, V.S…& Nychyk, N.A. (2007). Infektsiini khvoroby v praktytsi dilnychnoho i simeinoho likaria [Infectious diseases in practice of district and family doctor]. Ternopil: TDMU, Ukrmedknyha [in Ukrainian].
Advisory Committee on Immunization Practices (2011). General recommendations on immunization – recommendations of the ACIP. MMWR Recomm Rep., 60, 1-64.
Vasconcelos, P.F., Costa, Z.G., & Travassos da Rosa, E.S. (2001). Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. Journal of Medical Virology, 65, 598-604.
Huggins, J.W. (1989). Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Reviews of Infectious Diseases, 11, 750-761.
Ter Meulen, J., Sakho, M., & Koulemou, K. (2004) Activation of the cytokine network and unfavorable outcome in patients with yellow fever. The Journal of Infectious Diseases, 190, 1821-1827.
Julander, J.G. (2013). Experimental therapies for yellow fever. Antiviral Research, 97, 169-179.
Staples, J.E., Bocchini Jr, J.A., & Rubin, L. (2015). Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR, 64, 647-650.
Gotuzzo, E., Yactayo, S., & Córdova, E. (2013). Ecacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. The American Journal of Tropical Medicine and Hygiene, 89, 434-444.
World Health Organization Department of Immunization, Vaccines and Biologicals. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. July 2016.
Downloads
Published
Issue
Section
License
Автори, які публікуються у цьому журналі, погоджуються з наступними умовами:
- Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи, яка через [ВКАЖІТЬ ПЕРІОД ЧАСУ] з дати публікації автоматично стає доступною на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
- Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
